Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366483 | 0.88 | PDGFRB (0.57) | SMN1; SMN2ALDH1A1HPGDPDGFRBKDR | |
| SCHEMBL1369022 | 0.82 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1HPGDPDGFRBKDR | |
| SCHEMBL12620146 | 0.73 | TYMS (0.60) | PARP1TYMS | |
| SCHEMBL6649736 | 0.72 | TYMS (0.56) | SMN1; SMN2ALDH1A1HPGDKDM4EADORA3 | |
| SCHEMBL13915414 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1HPGDPDGFRBADORA3 | |
| SCHEMBL13539588 | 0.70 | POLB (0.47) | SMN1; SMN2ALDH1A1HPGDKDM4EADORA3 | |
| SCHEMBL3797825 | 0.69 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HPGDKDM4EADORA3 | |
| SCHEMBL13915418 | 0.69 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HPGDKDM4EADORA3 | |
| SCHEMBL18623608 | 0.69 | LMNA (0.69) | SMN1; SMN2ALDH1A1KDM4EADORA2ATP53 | |
| SCHEMBL311846 | 0.69 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1HPGDKDM4EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | SMN1; SMN2 4668/4885ALDH1A1 763/4885HPGD 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.